Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
IN8BIO, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
INAB
Nasdaq
8731
https://www.in8bio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for IN8BIO, Inc.
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
- Apr 24th, 2024 12:00 pm
INAB: Initiating Coverage – Enhancing the Insurgents of the Immune System
- Apr 22nd, 2024 10:04 am
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
- Apr 16th, 2024 8:05 pm
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
- Apr 9th, 2024 8:30 pm
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
- Mar 14th, 2024 8:00 pm
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
- Mar 5th, 2024 9:30 pm
IN8bio to Present at Upcoming Investor Conferences
- Feb 26th, 2024 1:00 pm
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
- Feb 14th, 2024 1:00 pm
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
- Jan 4th, 2024 1:00 pm
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
- Dec 11th, 2023 9:05 pm
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
- Dec 11th, 2023 2:00 pm
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
- Dec 7th, 2023 1:00 pm
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
- Dec 5th, 2023 1:00 pm
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
- Nov 20th, 2023 12:00 pm
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
- Nov 10th, 2023 12:00 pm
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 9th, 2023 9:00 pm
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- Nov 6th, 2023 1:00 pm
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- Nov 3rd, 2023 4:00 pm
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
- Nov 2nd, 2023 1:17 pm
IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium
- Nov 1st, 2023 12:00 pm
Scroll